---
title: "LifeSci Capital Remains a Buy on Definium Therapeutics (DFTX)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286649305.md"
description: "LifeSci Capital's Francois Brisebois has maintained a Buy rating on Definium Therapeutics (DFTX) with a price target of $38.00. The analyst consensus suggests a Strong Buy rating for the stock, with an average price target of $40.00. Brisebois has an average return of 2.4% and a 40.11% success rate on his recommendations."
datetime: "2026-05-16T14:35:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286649305.md)
  - [en](https://longbridge.com/en/news/286649305.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286649305.md)
---

# LifeSci Capital Remains a Buy on Definium Therapeutics (DFTX)

In a report released today, Francois Brisebois from LifeSci Capital maintained a Buy rating on Definium Therapeutics, with a price target of $38.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Brisebois covers the Healthcare sector, focusing on stocks such as Savara, Praxis Precision Medicines, and Opus Genetics. According to TipRanks, Brisebois has an average return of 2.4% and a 40.11% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Definium Therapeutics with a $40.00 average price target.

### Related Stocks

- [DFTX.US](https://longbridge.com/en/quote/DFTX.US.md)
- [SVRA.US](https://longbridge.com/en/quote/SVRA.US.md)
- [PRAX.US](https://longbridge.com/en/quote/PRAX.US.md)
- [IRD.US](https://longbridge.com/en/quote/IRD.US.md)

## Related News & Research

- [Definium Therapeutics (NASDAQ:DFTX) Issues Earnings Results](https://longbridge.com/en/news/285796112.md)
- [Is It Too Late To Consider Definium Therapeutics (DFTX) After Its 311% One Year Surge?](https://longbridge.com/en/news/283707382.md)
- [LifeSci Capital Sticks to Its Buy Rating for Spyre Therapeutics (SYRE)](https://longbridge.com/en/news/286679543.md)
- [Hemab Therapeutics Reports First Quarter 2026 Financial Results](https://longbridge.com/en/news/287208997.md)
- [Damora Therapeutics (DMRA) Receives a Rating Update from a Top Analyst](https://longbridge.com/en/news/286678740.md)